Rockville, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The anticoagulant reversal drugs market is likely to reach a valuation of US$ 1,137.35 Million in 2022. Furthermore, across the 2022-2032 period of assessment, growth is expected to accelerate at a whopping 15.0% CAGR, reaching US$ 4,601.22 Million. Bleeding disorders can happen as a result of some medications, such as blood thinners, which includes warfarin, heparin, and aspirin. The high risk of bleeding varies with the anticoagulant agent used. According to the National Center for Biotechnology Information (NCBI) data, the occurrence of bleeding for patients taking warfarin has been projected at 15-20% each year.
Life-threatening bleeding because of warfarin has been projected at a rate of 1-3% per year. Thus, increase in demand for anticoagulant therapies is further creating potential opportunities for reversal agents for anticoagulants. Increasing demand for anticoagulant reversal drugs in case of uncontrolled bleeding is expected to drive the market growth during the forecast period.
Download Sample Copy of This Report –
https://www.factmr.com/connectus/sample?flag=S&rep_id=4338
According to the World Health Organization (WHO), people over the age of 65 are the fastest demographic segment in the world. Between 2000 and 2050, the proportion of the world's population over the age of 60 is expected to double, increasing from about 11% to 22%. As per the reports of CDC, approximately 2% of people below 65 years of age have atrial fibrillation, while 9% of people who are above 65 years of age have the disease. It is also estimated that almost 12.1 million people will develop atrial fibrillation by 2030. As a result, the growing elderly population is driving the global anticoagulant reversal drugs market growth during the forecast period.
Key Takeaways from the Market Study
- According to Fact.MR, a CAGR of 7.7% was recorded for the Anticoagulant Reversal Drugs market from 2017-2022
- In FY 2023, the Anticoagulant Reversal Drugs market reached a valuation of US$ 1,137.35 Million
- The market is likely to register a Y-o-Y growth rate of 13.0% in 2023
- By Product, the Idarucizumab Segment is expected to dominate the market, documenting a 14.3% value CAGR
- As per Fact.MR’s projections, the market for Anticoagulant Reversal Drugs in North America will likely expand at a 14.8% CAGR
- The Anticoagulant Reversal Drugs market in Asia Pacific is expected to expand at an 14.7% CAGR
Competitive Landscape
Prominent players in the Anticoagulant Reversal Drugs Industry are taking advantage of the rapidly increasing demand for the Anticoagulant Reversal Drugs in various applications. To further their outreach, players are relying on collaborations, partnerships and acquisitions with existing small, medium and large-scale players. Some prominent market developments are as follows:
- In October 2021, Alveron Pharma BV raised EUR 3.9 Mn to fund the continued development of OKL-1111, a first in class drug to treat anticoagulant-related bleeding.
- In July 2020, VarmX, a renowned biotech company, raised EUR 32 Mn in series B financing to develop an innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants.
- In July 2020, Janssen Research and Development LLC began the Phase 1 clinical trial for the evaluation of the reversal of the anticoagulation effect of the drug JNJ-70033093 by 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa.
- In July 2020, Portola Pharmaceuticals Inc. announced the establishment of a permanent J-code (J7169) by the Centers for Medicare & Medicaid Services (CMS) for Andexxa, a recombinant coagulation factor Xa, that allows reimbursement in the hospital outpatient settings.
Get Customization on this Report for Specific Research Solutions –
https://www.factmr.com/connectus/sample?flag=RC&rep_id=4338
Prominent Service Players
- Bausch Health Companies, Inc.
- Pfizer, Inc.
- Fresenius Kabi AG
- Amneal Pharmaceuticals, Inc.
- Boehringer Ingelheim GmbH
- CSL Limited
- Octapharma AG
- Portola Pharmaceuticals, Inc.
- Perosphere Pharmaceuticals, Inc.
Key Segments Covered in the Anticoagulant Reversal Drugs Industry Survey
- By Product :
- Prothrombin Complex Concentrates
- Vitamin K
- Protamine
- Tranexamic Acid
- Idarucizumab
- Andexxa
- Others
- By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Others
Get Free Access of Complete Report –
https://www.factmr.com/checkout/4338
Global Anticoagulant Reversal Drugs Market Analysis and Forecast by Region
- North America Anticoagulant Reversal Drugs Market Size and Forecast, 2022-2032
- Germany Anticoagulant Reversal Drugs Market Size and Forecast, 2022-2032
- UK Anticoagulant Reversal Drugs Market Size and Forecast, 2022-2032
- France Anticoagulant Reversal Drugs Market Size and Forecast, 2022-2032
- Spain Anticoagulant Reversal Drugs Market Size and Forecast, 2022-2032
- Japan Anticoagulant Reversal Drugs Market Size and Forecast, 2022-2032
- China Anticoagulant Reversal Drugs Market Size and Forecast, 2022-2032
- Malaysia Anticoagulant Reversal Drugs Market Size and Forecast, 2022-2032
- Thailand Anticoagulant Reversal Drugs Market Size and Forecast, 2022-2032
- Australia Anticoagulant Reversal Drugs Market Size and Forecast, 2022-2032
More Insights Available
Fact.MR, in its new offering, presents an unbiased analysis of the global Anticoagulant Reversal Drugs market, presenting historical analysis from 2017 to 2022 and forecast statistics for the period of 2023-2033.
The study reveals essential insights on the basis of product (prothrombin complex concentrates, vitamin k, protamine, tranexamic acid, idarucizumab, andexxa, and others), by distribution channel (hospital pharmacies, retail pharmacies, and others), across five major regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).
Check out more related studies published by Fact.MR Research:
Diuretic Drugs Market - The growing prevalence and recurrence of kidney stones, heart failure, and high blood pressure is expected to be the major factor driving the growth of the diuretic drugs market over the forecast period. According to the World Health Organization, cardiac disease is the number one cause of death, globally. An estimated 17.2 million people die from cardiac diseases, representing a total of 31% of global deaths annually.
Large Macrolide Drugs Market - Clarithromycin and azithromycin are the derivatives of erythromycin. Others include spiramycin and telithromycin. They all are common types of drugs that are anti-bacterial and are used in the treatment of respiratory bacterial infections. Based on the distribution channel, large macrolide drugs are distributed by hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. They are effective against bacterial infections.
Optic Nerve Disorders Drugs Market - Rising number of instances of optic nerve disorders are indicating unabated demand for optic nerve disorders drugs in the coming years, thereby driving the optic nerve disorders drugs market. According to data by the World Health Organization (WHO), approx. 1.3 billion people suffer due to some sort of vision impairment. Among all the other possible causes, glaucoma (a condition leading to damage of optic nerves) has been identified as a prominent cause.
Cognitive and Memory Enhancer Drugs Market - Growing awareness about the advantages of cognitive and memory enhancer drugs for boosting mental and physical performance will also fuel their demand in years ahead. Nootropics is an emerging segment of brain enhancer drugs that are supposed to enhance brain functions with an additional boost. Also referred to as smart drugs, growing popularity of nootropics is expected to elevate the prospects for cognitive and memory enhancer drugs market in the years ahead.
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. We are committed to deliver insights that help businesses gain deeper understanding of their target markets. We understand that making sense of the vast labyrinth of data can be overwhelming for businesses. That’s why focus on offering insights that can actually make a difference to bottom-lines.
Specialties: Competition Tracking, Customized Research, Syndicated Research, Investment Research, Social Media Research, Business Intelligence, Industry Analysis, Thought Leadership.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
E: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
